Compugen (NASDAQ:CGEN) Issues Earnings Results

Compugen (NASDAQ:CGEN) announced its earnings results on Monday. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), FiscalAI reports. Compugen had a net margin of 47.97% and a return on equity of 53.13%. The business had revenue of $2.18 million for the quarter, compared to analysts’ expectations of $1.57 million.

Here are the key takeaways from Compugen’s conference call:

• Compugen said its MAIA-ovarian trial for COM701 is now enrolling at sites in the U.S., Israel, and France, and management said it remains on track to report interim median PFS data in Q1 2027.
• Management reiterated that COM701’s differentiated PVRIG biology may support activity in ovarian cancer, including in patients who are PD-L1 positive or negative, and noted the trial is not stratified by PD-L1 status.
• Compugen highlighted continued external validation of its partnered asset rilvegostomig, citing AstraZeneca’s AACR presentations and ongoing advancement across 11 phase III trials as supportive of the program’s potential.
• The company said its Gilead-partnered GS-0321 phase I dose-escalation study is progressing as planned, with Compugen having already received $90 million and eligible for up to $758 million more in milestones plus royalties.
• Compugen ended the quarter with about $134.9 million in cash and said its runway should fund operations into 2029, allowing continued investment in MAIA-ovarian, GS-0321, and its early-stage pipeline.

Compugen Stock Performance

Shares of Compugen stock opened at $2.73 on Wednesday. The stock has a market cap of $258.50 million, a price-to-earnings ratio of 7.39 and a beta of 2.79. The stock has a 50 day moving average price of $2.52 and a 200-day moving average price of $2.00. Compugen has a one year low of $1.29 and a one year high of $3.23.

Hedge Funds Weigh In On Compugen

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC lifted its holdings in shares of Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after acquiring an additional 359,785 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Compugen in the 4th quarter worth about $104,000. Marshall Wace LLP lifted its holdings in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Compugen in the 4th quarter worth about $84,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Compugen by 3.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after acquiring an additional 51,565 shares during the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Wall Street Analysts Forecast Growth

CGEN has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Truist Financial raised shares of Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Lake Street Capital began coverage on Compugen in a report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.